Zacks Investment Research on MSN
REPL stock soars on plans of BLA resubmission for melanoma combo drug
Shares of Replimune Group REPL soared 85.7% on Friday after the company announced that it had aligned with the FDA on the ...
Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy ...
Replimune announced it has reached an agreement with the U.S. Food and Drug Administration to resubmit a marketing ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Replimune (REPL) stock surged after the company announced plans to resubmit a marketing application for its lead asset, RP1, in the U.S. Read more here.
Track conference calls, annual meetings, summits, analyst days and other corporate events scheduled for Replimune Group Inc. Use the full market events calendar to scan activity across all tickers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results